Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Sinopharm Group Co's operating assets for the quarter that ended in Dec. 2025 was $48,496 Mil. Sinopharm Group Co's operating liabilities for the quarter that ended in Dec. 2025 was $26,301 Mil. Sinopharm Group Co's Total Assets for the quarter that ended in Jun. 2025 was $58,538 Mil. Therefore, Sinopharm Group Co's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.38.
Sinopharm Group Co Scaled Net Operating Assets Related Terms
Sinopharm Group Co Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Scaled Net Operating Assets Chart
SHTDY vs MCK, COR, CAH: Scaled Net Operating Assets Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Scaled Net Operating Assets vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.38 mean?
Sinopharm Group Co (SHTDY) has a Scaled Net Operating Assets of 0.38 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sinopharm Group Co and its competitors.
Is Sinopharm Group Co's Scaled Net Operating Assets too high?
Sinopharm Group Co's current Scaled Net Operating Assets is 0.38. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Scaled Net Operating Assets compare to MCK and COR?
Sinopharm Group Co's Scaled Net Operating Assets of 0.38 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Distribution company?
A good Scaled Net Operating Assets depends on the Medical Distribution industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current Scaled Net Operating Assets is 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.40, compared to a current price of $10.14 — trading 24.3% below its estimated fair value. The current Scaled Net Operating Assets is 0.38. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Scaled Net Operating Assets is 0.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDY) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $10.14 is trading 24.3% below its estimated GF Value™ of $13.40.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDY:
Scaled Net Operating Assets: 0.38
GF Value™: $13.40 vs. price of $10.14 (24.3% below fair value)
No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score
Get the complete analysis for SHTDY
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDY has been successfully added to your 
